Danish Diabetes and Endocrine Academy (DDEA) is headed by a Board of Directors (BoD) of seven members with a well-balanced and broad representation of stakeholders with regard to gender, age, national geography, and sector. 

Members' profile and competences

The BoD includes representation from early-career researchers, senior researchers, and clinicians, as well as universities, hospitals, and life science industry, across diabetes and other endocrinology fields.

The members have competence and experience as board members/chairpersons, researchers, or clinicians in diabetes and other endocrinology fields, education and talent development, innovation and entrepreneurship, fundraising, public-private partnerships, impact assessment, and Novo Nordisk Foundation-funded initiatives and strategies.

BoD responsibilities

• Defining and deciding the overall strategy and the strategy for DDEA’s four key activity classes and oversee its implementation, including approving the annual accounts and budget, the annual programme for the DDEA activities, and making the final decision on grant allocations.

• Performing an annual evaluation of DDEA and its organisation, including impact assessment of the success criteria, key performance indicators and other evaluation factors to decide whether the strategy for future activities needs adjusting.

Further information can be found in the Terms of References of the DDEA Board of Directors.